The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global blood gas and electrolyte analyzer market reached a value of US$ 1.85 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.76 Billion by 2027, exhibiting a CAGR of 6.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood gas and electrolyte analyzer market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, modality and end user.
Breakup by Product Type:
Breakup by Modality:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Modality, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at